Nephros Announces Inclusion in the Russell Microcap® Index
Nephros (Nasdaq: NEPH), a water technology and filtration company, announced its inclusion in the Russell Microcap® Index following the 2026 annual reconstitution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nephros (Nasdaq: NEPH), a water technology and filtration company, announced its inclusion in the Russell Microcap® Index following the 2026 annual reconstitution. Membership became effective after the US market close on June 26, 2026 and will remain in place for one year.
Inclusion also provides automatic membership in the appropriate Russell growth and value style indexes, with FTSE Russell determining index membership based mainly on market-capitalization rankings and style attributes. Nephros’ CEO stated the company believes this may support long-term shareholder value and increase visibility with potential institutional and other new investors.
Positive
- Inclusion in the Russell Microcap® Index effective June 26, 2026 close
- One-year index membership with automatic growth and value style index inclusion
- Management believes index inclusion may support long-term shareholder value
- Management expects increased visibility with potential institutional and new investors
Negative
- None.
Details
Market move: NEPH +4.41% in the Jul 6 session. Russell Microcap index inclusion
On Jul 6, the day this news came out, NEPH closed 4.41% above the previous close.
Data tracked by StockTitan Argus for the Jul 6 session.
Key Figures
- Index effective date
- June 26, 2026
- Inclusion in Russell Microcap Index became effective after U.S. market close
- Membership duration
- 1 year
- Russell Microcap Index membership term following 2026 annual reconstitution
- Reconstitution year
- 2026
- Added at conclusion of the 2026 annual Russell Microcap reconstitution
Historical Context
-
Company scheduled a virtual investor event showcasing its water safety model.
-
Highlighted ultrafiltration as a solution to emerging microplastic risks in water.
-
Reported higher revenue and modest profitability with pressure on gross margin.
-
Announced timing and access details for first-quarter 2026 results call.
-
Expanded Greater New York focus with new sales leader targeting $25M opportunity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH ORANGE, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that the company has been added to the Russell Microcap® Index at the conclusion of the 2026 annual reconstitution. Nephros’ inclusion in the index became effective after the US market closed on June 26, 2026.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
"We are pleased to be joining the Russell Microcap® Index, which follows a year of significant achievement with exciting growth potential ahead. We believe our inclusion will not only help deliver long-term value to our shareholders will but increase our visibility with potential institutional and other new investors," said Robert Banks, President and Chief Executive Officer.
About the Russell Indexes
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within medical and commercial markets, offering both proactive and emergency solutions for water management.
For more information about Nephros, please visit us at nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ beliefs regarding the potential growth of its business, the benefits to Nephros’ existing stockholders resulting from its inclusion in the Russell Microcap® Index and the potential to expand Nephros’ stockholder base, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, the extent to which financial results based on emergency response sales can be outside Nephros’ control, U.S. tariff and trade policy, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that it makes, except as may be required by law.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
robert.banks@nephros.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.